Small bowel non-Hodgkin's lymphoma remaining in complete remission by surgical resection and adjuvant rituximab therapy

• Published in: World journal of gastroenterology : WJG 2005-07, Vol.11 (28), p.4443-4444
• Main Authors: Nomura, Kenichi, Tomikashi, Koichi, Matsumoto, Yosuke, Yoshida, Naohisa, Okuda, Takashi, Sakakura, Chohei, Mitsufuji, Shoji, Horiike, Shigeo, Yamagishi, Hisakazu, Okanoue, Takeshi, Taniwaki, Masafumi
• Format: Article
• Language: English
• Subjects: Adult; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents - administration & dosage; Case Report; Combined Modality Therapy; Humans; Intestinal Neoplasms - drug therapy; Intestinal Neoplasms - pathology; Intestinal Neoplasms - surgery; Lymphoma, Non-Hodgkin - drug therapy; Lymphoma, Non-Hodgkin - pathology; Lymphoma, Non-Hodgkin - surgery; Male; Remission Induction; Rituximab
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.v11.i28.4443

A 44-year-old man was referred to our hospital with intermittent abdominal pain. Because distention of fluid- and gas-filled loops of small intestine was proved by X-ray, the patient was diagnosed as having small bowel obstruction. A laparotomy revealed a segmental stenosis in the jejunum, which showed diffuse thickening of the intestinal wall. Some mesenteric lymph nodes were swollen. Pathological examination was defined. We diagnosed diffuse large B-cell lymphoma based on the pathological findings of diffuse transmural infiltration of large lymphoid cells and flow-cytometric analyses. Rituximab was administered as adjuvant therapy at weekly doses of 375 mg/m2. Four cycles were performed every 6 mo and he remained CR. Rituximab may be effective as adjuvant therapy.